Apogee Therapeutics, INC Form 4 insider transactions

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold common stock in multiple transactions on April 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 1,590 shares of common stock at $30.48 per share on March 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold a portion of his common stock holdings on March 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, exercised stock options and sold a portion of his holdings under a pre-arranged trading plan.

Apogee Therapeutics CEO Michael Henderson sold 15,000 shares of common stock at an average price of $40.58 on February 5, 2025, according to a Form 4 filing.

Apogee Therapeutics CEO Michael Henderson exercised stock options on January 31, 2025, acquiring 8,500 shares of common stock.

Apogee Therapeutics CEO Michael Henderson sold shares of the company's common stock on January 8, 2025, according to a Form 4 filing with the SEC.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and sold shares under a pre-arranged trading plan.

Apogee Therapeutics director Mark McKenna purchased 20,000 shares of common stock in multiple transactions on December 12, 2024.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, acquired and disposed of company stock and stock options on December 11, 2024, according to a recent SEC filing.

Apogee Therapeutics CEO, Michael Henderson, was granted stock options for 357,036 shares, vesting over four years.

Apogee Therapeutics' Chief Financial Officer, Jane Pritchett Henderson, has been granted stock options for 124,962 shares.

Apogee Therapeutics has granted stock options to its Chief Medical Officer, Carl Dambkowski, for the purchase of 124,962 shares of common stock.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 6,665 shares of common stock at $46.07 per share on December 4, 2024, under a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold a total of 15,000 shares of common stock on December 4, 2024, under a pre-arranged 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on November 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold 15,000 shares of common stock on November 6, 2024, under a pre-arranged 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on October 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold shares of the company's common stock on October 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold a portion of his holdings in the company's common stock on September 4, 2024, under a pre-arranged trading plan.

Apogee Therapeutics CEO Michael Henderson sold shares of common stock on September 4, 2024, under a pre-arranged 10b5-1 trading plan.

Jane Henderson, CFO of Apogee Therapeutics, sold 6,000 shares of common stock on August 23, 2024, at a price of $48.26 per share.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on August 7, 2024, under a pre-arranged trading plan.

Apogee Therapeutics CEO Michael Henderson sold a portion of his common stock holdings on August 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold 15,000 shares of common stock on July 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on July 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director William Jones of Apogee Therapeutics acquired stock options for 10,370 shares of common stock on June 5, 2024, according to a recent SEC Form 4 filing.

Director Mark McKenna acquired options to purchase 10,370 shares of Apogee Therapeutics common stock on June 5, 2024.

Director Lisa Bollinger reports receiving a stock option grant for 8,112 shares of Apogee Therapeutics common stock.

Jennifer Fox, a director at Apogee Therapeutics, acquired options to purchase 10,370 shares of common stock on June 5, 2024.